[Prophylactic or pre-emptive therapy with azacitidine or FLT3 inhibitor after allogeneic hematopoietic stem cell transplantation for AML and MDS].

Strategies to prevent post-transplant relapse in acute myeloid leukemia and myelodysplastic syndromes

Maintenance therapy after allogeneic stem cell transplantation for relapse prevention in myeloid malignancies.

PURPOSE OF REVIEW Relapse remains the leading cause of treatment failure after allogeneic hematopoietic cell transplantation (HCT) for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), and outcomes after relapse are poor. This review summarizes and critically appraises current evidence for post-HCT main...

Novel targeted therapy and cellular immunotherapy enabling allogeneic hematopoietic stem cell transplantation for relapsed/refractory acute myeloid leukemia.

ABSTRACT Patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) are characterized by a disastrous prognosis. For most patients with R/R AML, allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative option. It is important to conduct mutational analysis again when the disease relap...

Allogeneic stem cell transplantation with post-transplantation cyclophosphamide in patients with acute myeloid leukemia achieving first complete remission after one versus two inductions: a study from the ALWP/EBMT.

In AML patients receiving alloHSCT with PTCy, outcomes were largely similar regardless of whether CR1 was achieved after one or two-induction courses, with relapse incidence being higher in patients requiring 2 inductions.

Progress in reprogramming failed graft-versus-leukemia immunity in acute myeloid leukemia relapse after allogeneic transplantation

A GVL Failure Framework is proposed that organizes posttransplant relapse into three biologically defined categories of immune escape, aligns matched cellular therapies with each, and overlays a separate clinical transplant-eligibility axis that sets the therapeutic goal.

Epigenetic Priming with Azacitidine Prior to Allogeneic Hematopoietic Stem Cell Transplantation for Myeloid Malignancies.

BACKGROUND Relapse remains the leading cause of treatment failure following allogeneic hematopoietic stem cell transplantation (alloHCT) for high-risk myeloid malignancies. Epigenetic dysregulation contributes to leukemogenesis and therapeutic resistance. OBJECTIVE OBJECTIVE: : To investigate whether pre-transplant e...